Latest Investigation News

Dimerix will provide continued access to its investigational drug DMX-200 for eligible patients with focal segmental glomerular sclerosis after completing the pivotal ACTION3 Phase 3 trial, supporting ongoing treatment ahead of regulatory approval.

Island Pharmaceuticals is progressing its broad-spectrum antiviral Galidesivir amid a severe Ebola outbreak, securing government approvals in Uganda and outlining a dual clinical and regulatory development pathway targeting multiple deadly filoviruses.

Cogstate Ltd smashed previous records with $89 million in net sales contracts for FY26, more than doubling the prior year. The company enters FY27 with a robust $118.5 million revenue backlog, signalling solid growth visibility.

Antipa Minerals’ updated Pre-Feasibility Study test-work validates a conventional gold-copper processing route with strong recoveries and reveals geotechnical improvements that could reduce underground mining at Minyari Dome.

Noxopharm has taken a key regulatory step by requesting a pre-IND meeting with the US FDA for its autoimmune drug candidate SOF-SKN, aiming to smooth the path for clinical development and boost its commercial appeal.

Nexalis Therapeutics has ended funding negotiations with Point8 Capital after failing to secure a formal agreement, while successfully completing its IRX-616a Phase 1 trial with no serious adverse events. The company is reassessing clinical priorities amid funding uncertainty.

Antipa Minerals’ latest Pre-Feasibility Study update reveals strong metallurgical results with gold recoveries up to 98% and improved geotechnical parameters that could reduce underground mining at Minyari Dome.

Telix Pharmaceuticals has gained FDA alignment to advance Part 2 of its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration-resistant prostate cancer, setting the stage for U.S. enrolment pending regulatory approval.

Stelar Metals has uncovered new tungsten mineralisation zones at its Hill of Leaders project in the Northern Territory, setting the stage for imminent assay results and drilling campaigns.

Multistack International has finalised the sale of nearly all its assets and shares in its Australian subsidiary to Willing Y Limited, marking a pivotal step in its strategic overhaul.

Mesoblast has received a Biologics License Application filing number from the FDA for rexlemestrocel-L, targeting life-threatening bleeding in end-stage heart failure patients with LVADs, advancing its regulatory journey with orphan drug and RMAT designations.

MRG Metals reveals strong total heavy mineral assay results from 57 auger holes at Fotinho, reinforcing a district-scale rare earth corridor across the Adriano-Fotinho area in Mozambique.